5HT(3) antagonism abolishes the emotion potentiated startle effect in humans
- PMID: 16572265
- DOI: 10.1007/s00213-006-0337-z
5HT(3) antagonism abolishes the emotion potentiated startle effect in humans
Abstract
Rationale: The serotonergic system has been implicated in emotional processing in animals and humans. Although the contribution of different receptor subtypes has been hypothesised, there have been few direct tests of this in human subjects.
Objectives: The current study aimed to explore the involvement of the serotonin type 3 (5HT3) receptor subtype in a battery of emotional processing tasks previously found to be sensitive to SSRI administration.
Materials and methods: Healthy volunteers were randomised to receive the 5HT3 antagonist, ondansetron (12 mg, oral), or placebo in a double blind between groups design. Emotional processing was assessed using three tasks: affective modulation of the startle reflex, emotional categorisation and memory and facial expression recognition. Subjective state ratings, blood pressure and pulse were also collected before and after ondansetron and placebo.
Results: Ondansetron was well tolerated and did not affect subjective measures of mood, anxiety or well-being in these healthy volunteers. However, the emotion potentiated effect was abolished in the volunteers receiving ondansetron. Facial expression recognition and emotional memory were not significantly affected.
Conclusions: These results suggest an involvement of 5HT3 receptors in certain aspects of fear processing in humans. These effects are consistent with anxiolytic actions of 5HT3 antagonism in animal models and suggest that the 5HT3 receptor may play a role in the effects of serotonergic manipulations on fear and anxiety.
Similar articles
-
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.Am J Psychiatry. 2004 Jul;161(7):1256-63. doi: 10.1176/appi.ajp.161.7.1256. Am J Psychiatry. 2004. PMID: 15229059 Clinical Trial.
-
Short-term NK1 receptor antagonism and emotional processing in healthy volunteers.Psychopharmacology (Berl). 2011 May;215(2):239-46. doi: 10.1007/s00213-010-2133-z. Epub 2010 Dec 15. Psychopharmacology (Berl). 2011. PMID: 21161182 Clinical Trial.
-
A single dose of citalopram increases fear recognition in healthy subjects.J Psychopharmacol. 2007 Sep;21(7):684-90. doi: 10.1177/0269881106074062. Epub 2007 Jan 26. J Psychopharmacol. 2007. PMID: 17259206 Clinical Trial.
-
Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers.Psychopharmacology (Berl). 2009 Jul;205(1):85-91. doi: 10.1007/s00213-009-1517-4. Epub 2009 Apr 1. Psychopharmacology (Berl). 2009. PMID: 19337726 Clinical Trial.
-
Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers.Psychopharmacology (Berl). 2008 Sep;199(4):495-502. doi: 10.1007/s00213-007-1058-7. Epub 2008 Jun 25. Psychopharmacology (Berl). 2008. PMID: 18575851 Clinical Trial.
Cited by
-
The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome.Gastroenterology. 2011 Jun;140(7):1943-51. doi: 10.1053/j.gastro.2011.03.011. Epub 2011 Mar 21. Gastroenterology. 2011. PMID: 21420406 Free PMC article.
-
Decreased startle modulation during anticipation in the postpartum period in comparison to late pregnancy.Arch Womens Ment Health. 2012 Apr;15(2):87-94. doi: 10.1007/s00737-012-0261-7. Arch Womens Ment Health. 2012. PMID: 22315106 Free PMC article.
-
Lamotrigine, an antiepileptic drug, inhibits 5-HT3 receptor currents in NCB-20 neuroblastoma cells.Korean J Physiol Pharmacol. 2017 Mar;21(2):169-177. doi: 10.4196/kjpp.2017.21.2.169. Epub 2017 Feb 21. Korean J Physiol Pharmacol. 2017. PMID: 28280410 Free PMC article.
-
Pharmacological evaluation of novel 5-HT3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery.J Pharm Bioallied Sci. 2015 Apr-Jun;7(2):103-8. doi: 10.4103/0975-7406.154429. J Pharm Bioallied Sci. 2015. PMID: 25883513 Free PMC article.
-
Affective cognition and its disruption in mood disorders.Neuropsychopharmacology. 2011 Jan;36(1):153-82. doi: 10.1038/npp.2010.77. Epub 2010 Jun 23. Neuropsychopharmacology. 2011. PMID: 20571485 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources